The Latest Cardiac and Vascular News
MONTRÉAL, Aug. 29, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. (“Acasti” […]
BASKING RIDGE, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a […]
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming investor conferences: 2018 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, […]
GORDON, Australia, Aug. 29, 2018 /PRNewswire/ — The American offshoot of Australian biotech Noxopharm, Nyrada, believes it is within reach of achieving a major advance in the treatment of cardiovascular disease. It has made important progress with a drug candidate known as NYX-330 that Nyrada believes may be the next breakthrough medication for […]
REDWOOD CITY, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the U.S Food & Drug Administration (FDA) for the Pantheris SV (Small Vessel) Lumivascular atherectomy system. Pantheris […]
KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego. FAST-FFR trial data will be presented in the Main Arena during the late-breaking science session that begins at 12 noon […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial. The CONVERGE IDE trial is a landmark prospective, randomized trial […]
AUSTIN, Texas, August 27, 2018 (GLOBE NEWSWIRE) – XBiotech Inc. (NASDAQ: XBIT) today announced the release of results indicating that leukocyte-derived Interleukin-1 alpha (IL-1⍺) is the cause clots that can cause a heart attack or stroke. The research was led by a world-renowned cardiovascular researcher, Dr. Peter Libby, Professor Mallinckrodt of […]
REDWOOD CITY, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that management of Avinger will present at the following investor conferences: Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & […]
AMSTERDAM and MUNICH, Aug. 28, 2018 /PRNewswire/ — Royal Philips (NYSE : PHG , AEX: PHIA), a global leader in health technology, today announced that the European Society of Cardiology has incorporated instantaneous wave-free ratio (iFR) into its updated revascularization guidelines. The new guidelines have provided the highest recommendation (class I A) for iFR alongside fractional flow reserve (FFR) […]
